An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection.
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2012
At a glance
- Drugs Pilaralisib (Primary) ; Voxtalisib (Primary)
- Indications Glioblastoma
- Focus Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 26 Jul 2012 Actual end date (1 Jun 2012)added as reported by ClinicalTrials.gov record.
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.